Browse CD163

Summary
SymbolCD163
NameCD163 molecule
Aliases MM130; CD163 antigen; hemoglobin scavenger receptor; macrophage-associated antigen; CD antigen CD163; Scaven ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Soluble CD163: Secreted ; SUBCELLULAR LOCATION: Cell membrane Single-pass type I membrane protein Note=Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.
Domain PF00530 Scavenger receptor cysteine-rich domain
Function

Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization, inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.; FUNCTION: After shedding, the soluble form (sCD163) may play an anti-inflammatory role, and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.

> Gene Ontology
 
Biological Process GO:0002526 acute inflammatory response
GO:0006898 receptor-mediated endocytosis
GO:0006953 acute-phase response
Molecular Function GO:0005044 scavenger receptor activity
GO:0038024 cargo receptor activity
Cellular Component GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030666 endocytic vesicle membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors
R-HSA-2168880: Scavenging of heme from plasma
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolCD163
NameCD163 molecule
Aliases MM130; CD163 antigen; hemoglobin scavenger receptor; macrophage-associated antigen; CD antigen CD163; Scaven ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD163 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD163 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29619406MelanomaPromote immunityA thyroid biopsy was performed based on ultrasound findings and cytopathology revealed unique features including abundant clusters of necrotic cells, lymphocytes and CD163-positive histiocytes.
21523763Pleural Malignant MesotheliomaInhibit immunityWithin MPM tumors, macrophages comprised 27% ± 9% of the tumor area and demonstrated an immunosuppressive phenotype with high expression of CD163, CD206, and interleukin-4 receptor α.
Summary
SymbolCD163
NameCD163 molecule
Aliases MM130; CD163 antigen; hemoglobin scavenger receptor; macrophage-associated antigen; CD antigen CD163; Scaven ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD163 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD163
NameCD163 molecule
Aliases MM130; CD163 antigen; hemoglobin scavenger receptor; macrophage-associated antigen; CD antigen CD163; Scaven ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD163 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7890.147
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7660.716
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8020.602
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1760.726
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4990.836
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0310.744
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0840.888
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2120.914
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4410.842
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1570.556
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7740.564
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1840.366
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD163 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.112.3-1.21
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.113.6-2.51
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21171923.5-4.51
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.533.34.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382721.17.413.70.175
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221327.315.411.90.68
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolCD163
NameCD163 molecule
Aliases MM130; CD163 antigen; hemoglobin scavenger receptor; macrophage-associated antigen; CD antigen CD163; Scaven ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD163. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD163
NameCD163 molecule
Aliases MM130; CD163 antigen; hemoglobin scavenger receptor; macrophage-associated antigen; CD antigen CD163; Scaven ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD163. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD163.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD163
NameCD163 molecule
Aliases MM130; CD163 antigen; hemoglobin scavenger receptor; macrophage-associated antigen; CD antigen CD163; Scaven ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD163. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD163
NameCD163 molecule
Aliases MM130; CD163 antigen; hemoglobin scavenger receptor; macrophage-associated antigen; CD antigen CD163; Scaven ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD163 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD163
NameCD163 molecule
Aliases MM130; CD163 antigen; hemoglobin scavenger receptor; macrophage-associated antigen; CD antigen CD163; Scaven ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD163 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD163
NameCD163 molecule
Aliases MM130; CD163 antigen; hemoglobin scavenger receptor; macrophage-associated antigen; CD antigen CD163; Scaven ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD163 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CD163.
ID Name Drug Type Targets #Targets
DB05389WF10Small MoleculeCD163, MAEA2